While the stock market has experienced some recent sell-offs, valuations remain stretched. So what’s a value investor to do? Today’s article highlights four of the fastest-growing companies “that combine strong earnings outlooks with valuations that remain far below nosebleed territory.” For these four stocks that are priced at a discount despite significantly better-than-average growth prospects – including a pharmaceutical company with a potential billion-dollar drug that has been shown to alleviate symptoms of ADHD within a week – CLICK HERE.